Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
$0.10
-5.1%
$0.10
$0.03
$0.19
$25.79M0.9375,460 shs15,021 shs
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$6.27
+8.4%
$5.83
$4.65
$10.24
$104.81M0.2672,443 shs72,677 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$3.98
-0.6%
$4.08
$3.35
$21.92
$102.83M0.8590,707 shs143,855 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$7.04
+3.2%
$5.36
$3.13
$26.05
$105.68M2.69315,538 shs336,840 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
0.00%-0.30%-7.12%+65.33%-41.65%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
0.00%+7.09%+6.55%+16.23%-3.62%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
0.00%-3.28%-16.32%-25.98%-80.15%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
0.00%+28.16%+17.07%+97.09%-66.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
0.1929 of 5 stars
0.03.00.00.00.01.70.0
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
2.3083 of 5 stars
3.54.00.00.01.90.80.0
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.1669 of 5 stars
3.61.00.00.00.00.81.3
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.0176 of 5 stars
3.53.00.00.01.11.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
0.00
N/AN/AN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
3.00
Buy$16.67166.03% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.17
Buy$22.50466.04% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
3.00
Buy$59.25742.10% Upside

Current Analyst Ratings Breakdown

Latest CHUC, JSPR, CTNM, and COYA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
6/20/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
6/9/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
5/19/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.00
5/15/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
5/15/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.00
5/13/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/13/2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $33.00
4/28/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/22/2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
$8.49M3.04N/AN/A($0.01) per share-9.92
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
$3.55M29.52N/AN/A$2.37 per share2.64
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M2.06N/AN/A$7.66 per share0.52
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$4.11 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
-$4.16M-$0.01N/AN/A-55.89%N/A-104.63%8/18/2025 (Estimated)
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%8/11/2025 (Estimated)
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$42.26M-$1.97N/AN/AN/AN/A-24.59%-23.49%8/12/2025 (Estimated)
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$71.27M-$5.24N/AN/AN/AN/A-109.45%-89.82%8/12/2025 (Estimated)

Latest CHUC, JSPR, CTNM, and COYA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/29/2025Q4 2024
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
N/A-$0.01N/A-$0.01N/A$1.78 million
5/14/2025Q1 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
5/13/2025Q1 2025
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million
5/12/2025Q1 2025
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$1.17-$1.41-$0.24-$1.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
N/AN/AN/AN/AN/A
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
N/A
0.51
0.06
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
N/A
8.84
8.84
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
21.47
21.47
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
4.31
4.31

Institutional Ownership

CompanyInstitutional Ownership
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
7.80%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
39.75%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%

Insider Ownership

CompanyInsider Ownership
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
20.90%
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
12.00%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11.30%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
40259.95 million205.62 millionNot Optionable
Coya Therapeutics, Inc. stock logo
COYA
Coya Therapeutics
616.73 million14.72 millionNot Optionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3125.87 million22.95 millionN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2015.02 million14.33 millionOptionable

Recent News About These Companies

Analysts Offer Predictions for JSPR FY2026 Earnings
Jasper Therapeutics files $300M mixed securities shelf

New MarketBeat Followers Over Time

Media Sentiment Over Time

Charlie's stock logo

Charlie's OTCMKTS:CHUC

$0.10 -0.01 (-5.07%)
As of 07/3/2025 12:22 PM Eastern

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

Coya Therapeutics stock logo

Coya Therapeutics NASDAQ:COYA

$6.26 +0.49 (+8.39%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$6.05 -0.22 (-3.50%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$3.98 -0.03 (-0.63%)
Closing price 07/3/2025 02:42 PM Eastern
Extended Trading
$4.07 +0.10 (+2.42%)
As of 07/3/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$7.04 +0.22 (+3.17%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$6.90 -0.13 (-1.86%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.